Wedbush Weighs in on Apellis Pharmaceuticals, Inc.'s FY2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Investment analysts at Wedbush dropped their FY2025 EPS estimates for Apellis Pharmaceuticals in a report released on Wednesday, April 17th. Wedbush analyst L. Chico now expects that the company will earn $2.23 per share for the year, down from their prior estimate of $2.24. Wedbush currently has […]

Related Keywords

United States , American , Adamj Townsend , Robertw Baird , James George Chopas , Securities Exchange Commission , Hedge Funds Weigh In On Apellis Pharmaceuticals , Apellis Pharmaceuticals Inc , Apellis Pharmaceuticals Stock Performance , Charles Schwab Investment Management Inc , News Ratings For Apellis Pharmaceuticals Daily , Goldman Sachs Group , Profund Advisors , Nasdaq , Apellis Pharmaceuticals , American Investors Co , Wynnefield Capital Inc , Jefferies Financial Group , Free Report , Apellis Pharmaceutical , Get Free Report , Financial Group , George Chopas , Exchange Commission , American Investors , Schwab Investment Management , Apellis Pharmaceuticals Daily ,